Sie sind bereits registriert?
Loggen Sie sich mit Ihrem Universimed-Benutzerkonto ein:
Sie sind noch nicht registriert?
Registrieren Sie sich jetzt kostenlos auf universimed.com und erhalten Sie Zugang zu allen Artikeln, bewerten Sie Inhalte und speichern Sie interessante Beiträge in Ihrem persönlichen Bereich zum späteren Lesen. Ihre Registrierung ist für alle Unversimed-Portale gültig. (inkl. allgemeineplus.at & med-Diplom.at)
KRAS G12C Inhibitor Shows Modest Activity in Pancreatic Cancer
RAS mutations are ubiquitous in solid tumor malignancies and until recently were not thought to be druggable targets. Sotorasib is a small molecule KRAS G12C inhibitor that has demonstrated activity in non–small-cell lung cancer and, more recently, colorectal cancer.
Investigators now report results of an industry-sponsored, open-label, single-arm, phase 1–2 trial evaluating the safety and efficacy of oral sotorasib in KRAS p.G12C–mutated advanced pancreatic cancer. The trial included 38 patients treated at 25 centers in 7 countries; median age was 66, most patients (76%) were men, most (82%) had hepatic metastases, and most (79%) had received two or more lines of prior chemotherapy.
The primary endpoint, centrally confirmed objective response, was observed in 21% of patients, all of whom had a partial response. Median time to response was 1.5 months, and median duration of response was 5.7 months. Tumor shrinkage of any amount was seen in 79% of patients. Median progression-free survival was 4 months. Treatment-related grade 3 adverse events occurred in 16% of patients and included diarrhea and fatigue.
A modest signal of activity is seen for sotorasib in KRAS p.G12C–mutated pancreatic cancer, indicating that further study of this agent and target are warranted.
Strickler JH et al.
Title: Sotorasib in KRAS p.G12C–mutated advanced pancreatic cancer.
Source: N Engl J Med 2023 Jan 5; [e-pub]. (Abstract/FREE Full Text)